Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of mannose glucuronic acid oligosaccharides and polysaccharides and derivatives in preparation of drugs for treating and/or preventing aging

A technology of uronic acid oligosaccharide and uronic acid polysaccharide, applied in the field of pharmacy, can solve problems such as large side effects and general effects, and achieve the effects of small toxic side effects, safe sources and high yield

Pending Publication Date: 2022-01-18
ZHEJIANG UNIV
View PDF3 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] In order to solve the problem of large side effects and general effect of existing anti-aging drugs, we propose a kind of application of mannoglucuronic acid oligosaccharides and polysaccharides and their derivatives in the preparation of drugs for treating and / or preventing aging

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of mannose glucuronic acid oligosaccharides and polysaccharides and derivatives in preparation of drugs for treating and/or preventing aging
  • Application of mannose glucuronic acid oligosaccharides and polysaccharides and derivatives in preparation of drugs for treating and/or preventing aging
  • Application of mannose glucuronic acid oligosaccharides and polysaccharides and derivatives in preparation of drugs for treating and/or preventing aging

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0048] Embodiment 1: Preparation of mannoglucuronide oligosaccharides

[0049] Dried kelp and other brown algae were extracted with 30 times the mass of distilled water at 100°C for 3 hours to remove the alginate, the extract was filtered, dialyzed, concentrated, added ethanol to a final concentration of 75% and precipitated, and the precipitate was collected after standing for 12 hours , sink to obtain fucoidan sulfate ester by vacuum drying. Dissolve the fucoidan sulfate sample in a sulfuric acid solution with a mass concentration of 4% (the ratio of solid to liquid is 60mg / mL), heat and reflux for 5 hours, neutralize with barium hydroxide to PH=6-7, centrifuge, and concentrate the supernatant To one-fifth of the original volume, the concentrated solution was subjected to active carbon column chromatography, firstly equilibrated with distilled water, and then eluted with a gradient of 50%-90% ethanol, and the 50%-90% ethanol eluate was concentrated to five parts of the origi...

Embodiment 2

[0055] Embodiment 2: Preparation of mannoglucuronide polysaccharide

[0056] Dissolve the fucoidan sulfate obtained in Example 1 in a sulfuric acid solution with a mass concentration of 4% (the ratio of solid to liquid is 60 mg / mL) and heat to reflux for 4 hours, neutralize with barium hydroxide to PH=6-7, and centrifuge , the supernatant was concentrated to a small volume, and the concentrated solution was loaded on DEAE Sepharose Fast Flow (DEAE Sepharose gel, washed with water, 0.2M sodium chloride and 2M sodium chloride were eluted, and the 2M eluent was prepared by dialysis of a 500Da dialysis bag Obtain mannose glucuronide polysaccharide GMn (7.0kDa), the sample is carried out 1 H-NMR, 13 C-NMR, two-dimensional NMR and GPC-HPLC, etc. like image 3 and Figure 4 as shown, 1 H-NMR, 13 C-NMR is hydrogen nuclear magnetic resonance spectrum and carbon 13 nuclear magnetic resonance spectrum respectively. like Figure 5 As shown, the two-dimensional HMBC (1H detected he...

Embodiment 3

[0059] Example 3: Mannoglucuronide poly(oligo)saccharides can alleviate the decline in the viability of β cells caused by hydrogen peroxide

[0060] Treat MIN6 cells with mannose glucuronide poly(oligo)saccharides of the present invention at a concentration of 100 μg / ml, and the cell viability is not affected, indicating that the concentration has no cytotoxic effect ( Figure 9 A); then mannoglucuronide poly(oligo)saccharides are intervened with H 2 o 2 After pretreatment of islet β cells for 24 hours, mannoglucuronide poly(oligo)saccharides had a significant enhancement effect on cell viability ( Figure 9 B), if Figure 9 shown.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of mannose glucuronic acid oligosaccharides and polysaccharides and derivatives in preparation of drugs for treating and / or preventing aging, and aims to solve problems of great side effects and general effects of existing anti-aging drugs. The mannose glucuronic acid oligosaccharides and polysaccharides and derivatives have a remarkable anti-aging effect, is small in toxic and side effects, safe and effective, and can be used for preparing anti-aging medicines. A preparation process is simple, yield is high, and source is safe.

Description

technical field [0001] The invention relates to the field of pharmacy, in particular to the application of mannoglucuronic acid oligosaccharides, polysaccharides and derivatives in the preparation of medicines for treating and / or preventing aging. Background technique [0002] After entering the 21st century, human beings are facing the severe challenge of population aging. Many countries (including my country) have entered an aging society, and the elderly aged ≥60 account for more than 10% of the total population. At present, the elderly in my country (including some middle-aged people) are seriously troubled by aging, which directly affects their health status and quality of life. How to fully elucidate the pathogenesis of aging and how to improve the health status and quality of life of the elderly are the problems that current researchers need to focus on. In recent years, with the development of science and technology and the continuous improvement of research methods...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/702A61K31/715A61P39/06A61K31/737
CPCA61K31/702A61K31/715A61P39/06A61K31/737
Inventor 张文静周嘉强金维华吴楠
Owner ZHEJIANG UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com